Cytophage Sees Its Bacteriophages Used As Treatment In Canada Under Single Subject Clinical Trial
FULL DISCLOSURE: This is sponsored content for Cytophage Technologies.
For the first time in Canadian history, bacteriophage therapy is slated to be utilized to assist a patient suffering from a severe bone and joint infection related to a prosthetic. The therapy, to be conducted at The Ottawa Hospital, is being lead by principal investigator Dr. Marisa Azad, an infectious diseases clinician-scientists, whom will be utilizing bacteriophages provided by Cytophage Technologies (CSE: CYTO).
The treatment is to be conducted under a single subject clinical trial that has been developed and approved by The Ottawa Hospital Research Institute and Health Canada. The patient is set to be the only unit of observation within a study that is to investigate the efficacy of a course of treatment to combat an antibiotic resistant infection, for which all other treatment methods have failed. The approved treatment will see bacteriophages utilized and studied for their ability to destroy methicillin-resistant Staphylococcus epidermidis, or MRSE, bacteria.
The first treatment dose was reportedly provided to the patient this week, with treatment to be provided for two additional weeks. The phages to be used in the treatment and study were exclusively provided by Cytophage, and have been tested for their ability to destroy MRSE.
“This is an important breakthrough for people who suffer from drug-resistant prosthetic joint infections in that a new treatment regime is being introduced that will target these difficult to treat infections. We hope to make a significant difference in the quality of life of patients who are living with this type of infection,” commented Dr. Steven Theriault, CEO of Cytophage Technologies.
Approximately 3% of hip and knee replacement surgeries are estimated to require additional intervention in the form of treatment of antibiotic resistant infections. If left untreated, such infections can lead to to amputation or death.
Cytophage Technologies last traded at $0.50 on the CSE.
FULL DISCLOSURE: Cytophage Technologies is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cytophage Technologies. The author has been compensated to cover Cytophage Technologies on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
